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Abstract:  Few EU countries meet targets for saturated fatty acid (SFA) intake. Dairy 
products usually represent the single largest source of SFA, yet evidence indicates that milk 
has cardioprotective properties. Options for replacing some of the SFA in milk fat with  
cis-monounsaturated fatty acids (MUFA) through alteration of the cow’s diet are examined. 
Also, few people achieve minimum recommended intakes (~450–500 mg/d) of the long 
chain n-3 polyunsaturated fatty acids (PUFA) eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA). Enrichment of EPA+DHA in poultry meat via bird nutrition 
is described and how this would impact on habitual intake is discussed.  
Keywords: lipids; animal nutrition  
 
 
1. Introduction 
 
Public health nutrition is facing multiple and major challenges. There are in particular two major 
forces at work, the rapidly increasing burden of obesity and the increasing age of populations. Both 
trends increase the risk of chronic disease substantially and mean that diet, a key moderator of risk will 
play an increasingly important role. Data from WHO/FAO [1] suggest that by 2020 chronic diseases 
will account for almost 75% of all deaths worldwide with the vast majority being attributable to 
cardiovascular disease (CVD) with the associated rapid increase in the obesity/type 2 diabetes 
syndrome being particularly worrying as it is now also beginning to affect younger people. In the UK, 
the recent Foresight Report on obesity predicts that by 2050 some 55% of UK adults will be obese [2]. 
Similarly projections to 2050 of the age structure of the EU 25 suggests that its old-age dependency 
ratio (the number of people 65 and over relative to those between 15 and 64) is projected to double to 
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54% by 2050 [3]. The outcome of these trends will, if not moderated, lead to unsustainable costs of 
health care. Already, CVD costs the EU some €200 billion/year in direct and indirect charges [4]. 
It has been known for many years that diet plays a key role as a risk factor for chronic disease. In 
particular the effect of dietary fat in terms of both amount and type on the risk of chronic disease had 
much attention. Most attention has been focused on CVD though now it is recognised that effects of 
dietary fatty acids can be more widespread and subtle including effects on insulin sensitivity [5] and 
brain function [6]. Animal-derived foods contribute a substantial part of dietary fat in many countries 
and this has often been believed to be associated with increased chronic disease. This paper will focus 
on issues concerning intake of SFA and the long chain n-3 fatty acids (EPA and DHA) and examine 
opportunities to modify the composition of animal fats through animal nutrition in ways which may 
bring benefits in relation to long term health. 
 
2. Saturated Fatty Acids and Chronic Disease 
 
There is consistent evidence that dietary SFA increase the concentrations of serum LDL- 
cholesterol (LDL-C), an identified predictor of CVD risk and of coronary heart disease (CHD) in 
particular [7]. Until recently most attention has focused on LDL-C. However a meta-analysis of 60 
selected human studies [8] confirmed that when dietary carbohydrates are substituted by an 
isoenergetic amount of C12:0 to C16:0 SFA, an increase in LDL-cholesterol does occur, but crucially 
the study also showed that there was a concomitant increase in the protective HDL-cholesterol   
(HDL-C). These workers argued that the ratio of total cholesterol to HDL-C provides the best predictor 
of the effect of dietary fatty acids on the risk of CHD. This interpretation indicates that the effects of 
C12:0 and C14:0 fatty acids may be rather beneficial as they both lower the total to HDL-C ratio 
whilst the opposite is the case for C16:0. The meta-analysis of Mensink et al. [8] also showed that 
overall, the risk of CHD would be most effectively reduced by the replacement of dietary SFA with 
either cis-MUFA or PUFA. The benefits of the two replacement strategies in terms of the resulting 
serum cholesterol profile, was similar.  
The replacement of SFA by either cis-MUFA or PUFA may have other beneficial outcomes. As 
noted above there is now some evidence that high intake of SFA may also be associated with reduced 
insulin sensitivity, a key factor in the development of the metabolic syndrome [9]. There is 
epidemiological evidence to support the association between high SFA intake and impaired glucose 
tolerance [10-12] and some intervention evidence. In a study involving 162 healthy subjects [5] given 
diets rich in SFA (from butter and margarine) or cis-MUFA (from high oleic sunflower oil) those on 
the SFA diet had significantly impaired insulin sensitivity (–10%) whilst those on the cis-MUFA diet 
showed no change. It is noteworthy however that the favourable effects of cis-MUFA were not seen in 
subjects with a high fat intake (>37% of energy intake). The same moderating effect of dietary fat 
intake has also been reported recently from the Lipgene study [13].  
Despite the well publicised benefits of limiting SFA intake, populations in many parts of the EU 
still fail to meet dietary targets. Dietary targets vary from <11% of energy intake (EI) in the UK 
(population mean), <10% of EI [1] to as low as <7% of EI as recommended by the American Heart 
Association [14]. Table 1 shows SFA intake in various EU countries based on the TRANSFAIR   
study [15] and indicates that only Italy, Portugal, Spain and Greece achieve the target of <11% of EI. Nutrients 2009, 1                              
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In the UK it was reported that about 78 and 74 % 0f men and women respectively exceeded the mean 
population target (<11% EI) [16]. Of great concern in the UK is the fact that children exceed the target 
by an even greater degree [17]. There does seem therefore considerable scope for reduction in   
SFA intake.  
 
Table 1. Intakes of saturated fatty acids (SFA) and the proportion supplied by dairy 
products in 11 EU Member States (adapted from [15]). 
Country Male  (m) 
Female (f) 
SFA intake (g/d) SFA intake (% 
energy intake) 
SFA from dairy 
 (% total) 
Belgium m  45.0  15.3  30.2 
 f  35.9 15.5  30.2 
Finland m  32.9  12.5  44.9 
 f  25.2 12.8  44.9 
France m  34.2  15.0  56.7 
 f  25.9 15.8  56.7 
Germany m  49.0  17.5  57.1 
 f  39.2 18.6  57.1 
Greece m  22.6  10.5  27.4 
 f  24.1 12.9  27.4 
Italy m+f  30.9  10.6  47.3 
Netherlands m  40.0  13.9  33.9 
 f  30.7 14.3  33.9 
Portugal m  28.1  11.2  32.5 
Spain m+f  33.5  11.7  27.5 
Sweden m  37.7  15.0  48.5 
 f  27.8 14.5  48.5 
UK m+f  27.1  13.2  38.8 
Overall mean    33.5  14.1  41.3 
 
2.1. Milk and Dairy Products as Sources of Saturates 
 
Based on the TRANSFAIR study [15] Table 1 also shows the contribution to SFA intake made by 
milk and dairy products. The study also confirmed that on average milk fat contributed about 41% of 
all SFA and often contributes the single largest source of SFA. Thus logically, reducing the intake of 
SFA would simply require a reduction in consumption of milk and dairy products. However it is 
recognised that these foods are also key sources of other nutrients such as calcium and vitamin B12 [18].  
Moreover there is now convincing epidemiological evidence that high intake of milk can provide 
long term reductions in the risk of CVD. Recently, from a meta-analysis of 15 studies the relative risk 
of stroke and heart disease in subjects with high milk or dairy consumption was shown to be 0.79 
(95% CI 0.75, 0.82) and 0.84 (95% CI 0.76, 0.93) respectively, relative to the risk in those with low 
consumption [19]. Four studies reported incident diabetes as an outcome, and the relative risk in the Nutrients 2009, 1                              
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subjects with the highest intake of milk or diary foods was 0.92 (95% CI 0.86, 0.97). Set against the 
proportion of total deaths attributable to the life-threatening diseases in the UK, vascular disease, 
diabetes and cancer, Elwood et al. [19] concluded that the results provide evidence of an overall 
survival advantage from the consumption of milk. Thus simply reducing milk/dairy consumption in 
order to reduce SFA intake is not likely to produce benefits overall. It should be noted however that 
the epidemiological evidence relates mainly to milk and in the UK at least, cheese and butter provide 
most of the dairy-derived SFA [16]. 
Based on the above evidence it would seem that changing the fatty acid composition of dairy foods 
to replace some SFA with cis-MUFA could provide a useful way to reduce SFA intake whilst retaining 
the cardioprotective benefits of milk. This possibility has recently been reviewed [20]. Based on the 
rather limited number of intervention studies with milk/milk products with SFA reduced from typically 
70 to 55% of total fatty acids and cis-MUFA increased from typically 20 to 33% of total fatty acids, 
the review concluded that there was considerable potential for lower SFA dairy products to reduce 
population SFA intakes and potentially CHD burden. As part of a modelling exercise it was predicted 
that in the EU 27 reductions of some 10,500 and 3,900 deaths from CHD and stroke per annum, 
respectively, could result from such a strategy [21].  
 
2.2. Modifying Milk Fatty Acid Composition 
 
Milk fat typically contains 70-75 % SFA, 20-25% MUFA and small (2–5%) amounts of PUFA. 
Fatty acids in milk fat originate from two sources, either by direct incorporation from the peripheral 
circulation or from de novo synthesis in the mammary gland using short chain (C2:0 and C4:0) 
precursors. Mammary de novo synthesis accounts for all C4:0 to C12:0 fatty acids, most of the C14:0 
and typically about half of C16:0 secreted in milk, while all C18 and longer chain fatty acids are 
derived entirely from circulating plasma lipids [22]. Due to extensive biohydrogenation of dietary 
unsaturated fatty acids by bacteria in the rumen, C18:0 is, under most conditions, the predominant long 
chain fatty acid available for absorption but the activity of stearoyl Co A (Δ-9) desaturase in mammary 
secretory cells converts a considerable amount of C18:0 to cis-9 C18:1 [23]. As noted above, the 
production of reduced-SFA dairy products could potentially be of large public health benefit. This can 
be achieved by increasing the supply of long chain fatty acids (of chain length C18 and above) to the 
mammary gland which inhibits the synthesis of short and medium chain saturates [24]. Thus use of oil 
seeds in cows’ diets typically produces reductions in the SFA content of milk fat from 70 to 50% (see 
review [25]). A recent study [26] examined the effect of form of rapeseed lipid in the diet of the dairy 
cow on the reduction in SFA and increase in cis-MUFA that could be achieved. The treatments were 
no rapeseed lipid (control) or rape lipid in the form of rapeseed oil, whole, unprocessed rapeseeds or 
milled rapeseeds. Some key results are summarised in Table 2. It is clear that using whole, 
unprocessed rapeseed is not a viable option but the other two rapeseed lipid forms reduced SFA 
(notably palmitic acid) and increased cis-MUFA (notably oleic acid). 
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Table 2. Effect of form of rapeseed lipids in the diet on milk fatty acid composition 
(g/100g fatty acids). (from [26]) 
Fatty acid  Treatment
1 SEM
2  P
3 
Control RO  WR  MR 
Σ ≤ 14:0  22.6
a 18.2
c 26.2
b 21.3
a 0.53  ** 
16:0 34.5
a 19.8
c 31.1
b 21.6
c 0.64  *** 
18:0 9.8
a  14.6
b 10.8
a 15.5
b 0.32  *** 
18:1 trans total 4.1
a 10.0
c 3.2
a 6.4
b 0.40  *** 
18:1 cis total  20.8
a  26.9
b 18.9
a 25.6
b 0.67  *** 
Σ saturates  69.6
a 55.6
c 71.7
a 61.5
b 0.86  *** 
Σ cis MUFA  22.7
a 29.2
b 21.4
a 27.7
b 0.75  *** 
Σ trans MUFA  4.4
a 10.5
c 3.5
a 6.8
b 0.40  *** 
n-6:n-3 PUFA  4.2  2.4  1.6  5.3  1.32  NS 
1  Diets containing none (control) or rape lipid in the form of rapeseed oil (RO), whole rapeseeds (WR) or 
milled rapeseeds (MR). 
2  Standard error of the mean for n = 16 measurements, 6 error degrees of freedom. 
3  **P < 0.01 and ***P < 0.001, NS = not significant (P > 0.05). 
abc Means within row not sharing common roman superscripts differ significantly (P < 0.05). 
 
3. Long Chain n-3 Fatty Acids and Chronic Disease 
 
In the 1960’s and 70’s a number of studies demonstrated that consumption of fish was associated 
with a reduced risk of CHD in the Greenland Eskimos, despite an overall diet rich in fat [27,28]. This 
work led to the concept that the long chain (LC, carbon chain length 20) n-3 PUFA, in particular EPA 
(C20:5) and DHA (C22:6) typically found in marine foods were responsible for the observed 
cardioprotective effects. More recently, beneficial effects have been widely reported and include anti-
atherogenic, anti-thrombotic and anti-inflammatory effects and overall, increased intakes leading to 
reduced risk of CHD (for a review, see [29]).  
Evidence is also accumulating that the intake of EPA and DHA may influence cognitive function in 
the elderly. The Zutphen Elderly Study examined fish consumption in 210 males, aged 70–89 y in 
1990, along with estimates of cognitive function in 1990 and 1995 [6]. A significant (P < 0.01) 
positive linear trend was seen for the relationship between EPA+DHA intake and cognitive ability with 
a mean difference in intake of about 380 mg/d being associated with a 1.1-point difference in 
cognition. This study [6] concluded that moderate intakes of EPA+DHA may delay the decline in 
cognitive function in elderly men. Recent studies have however not shown an association between 
EPA/DHA intake and long term dementia risk [30,31].  
The essential dietary component α-linolenic acid (C18:3 n-3, ALNA) can in theory be desaturated 
and elongated to EPA and DHA, but recent studies and reviews [32-34] have concluded that whilst the 
principal role of ALNA is indeed as precursor for EPA/DHA, the efficiency of conversion of ALNA to 
EPA is very low, especially in men, and that further transformation to DHA is often minimal. Indeed it 
was concluded that ALNA is probably a quite limited source of EPA/DHA in humans [33] which Nutrients 2009, 1                              
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strongly suggests that these fatty acids should now be regarded as dietary essential. This is supported 
by the systematic review of Wang et al. [35] which concluded that increased consumption of n-3 fatty 
acids from fish or fish oil supplements, but not from ALNA, reduces the rates of all cause mortality, 
cardiac and sudden death and possibly stroke. 
Givens and Gibbs [36] reviewed the current recommended intakes of EPA+DHA. Where such 
recommendations are made, typically they are in the region of 500 mg/d although there is evidence of 
benefits from considerably higher intakes [29]. A recent study into the establishment of a dietary 
reference intake for EPA+DHA also concluded that the most international recommendations are   
~500 mg/d [34] although interestingly, the very recent scientific opinion from the European Food 
Safety Authority proposed a labelling reference intake for EPA+DHA of only 250 mg/d [37]. In the 
UK the target intake is 450 mg/d which is consistent with the consumption of two portions of fish per 
week, one of which is oil-rich. No consideration has yet been given to dietary recommendations in 
relation to brain function due to the relative paucity of data in this area. 
 
3.1. Current Intakes of LC-n-3 Fatty Acids 
 
The evidence relating to current intakes of EPA and DHA in various parts of the world has also 
been reviewed [36]. The data are summarised in Table 3. Some of the variability in estimated mean 
intake is likely to be due to the use of different food consumption surveys which suggest different 
levels of consumption of the key food types. Of note are the recommendations of SACN/COT [29] that 
canned tuna should be excluded from the oil-rich fish food category which makes it possible that some 
of the studies substantially overestimated EPA+DHA intake. It is also very important to realise that 
estimates of mean intake may not be very helpful. For example, in the UK, it was found that only 
about 27% of the adult population consume any oil-rich fish [29] and thus for the vast majority of the 
adult population the daily intake will probably at best be about 100 mg. A similar effect was seen in 
Belgian women [38]. Notably, in non-consumers of oil- rich fish in the UK, about half of the estimated 
100 mg/d intake was provided by animal-derived foods, poultry meat in particular [39]. It is likely that 
much of the LC n-3 fatty acids found in poultry meat from birds which did not have fish oil in their 
diets is due to the diet containing fishmeal which contains some residual fish oil. In 2004 some 48000t 
of fish meal (25 % of total use) was used in the UK for poultry diets [40] although this has declined 
considerably since. Overall, it is clear that in many areas and central Europe in particular, intake of 
EPA+DHA is considerably sub-optimal and this may be a key public health nutrition issue. 
 
Table 3. Recent estimated daily intakes of EPA + DHA in various countries (from [36]). 
Country  Details  Intake of EPA + 
DHA(mg/person/d) 
UK  Adults, 19-64 years, mean  244 
UK  Females, 19-24 years, mean  109
 
Belgium  Females, 18-39 years, mean  209 Nutrients 2009, 1                              
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Table 3. Cont. 
Belgium  Females, 18-39 years, median  50 
Belgium  Children 4-6.5 years, mean  75 
France  Women 45-63 years  344 
Australia Adults  143 
N. America  Adults  200 
Central Europe  Adults  250 
Northern Europe  Adults  590 
Japan Adults  950 
 
3.2 Enriching Animal-Derived Foods with of EPA and DHA 
 
Many studies have examined increasing the EPA and DHA concentration in animal-derived foods 
as a means of increasing daily intake (see for e.g. reviews [41,42]) although few have connected the 
potential for enrichment with current and projected patterns of food consumption. Assuming that 
consumption of enriched foods would be the same as that of normal foods, the potential for enrichment 
of a wide range of animal-derived foods has been calculated and how these may contribute to 
additional EPA+DHA intake in the UK [38]. The findings for milk and milk products, meat and eggs 
are summarised in Table 4.  
 
Table 4. Potential mean intakes of EPA and DHA by adults in the UK from enriched 
animal-derived foods (from [39]). 
Food Intake 
(g/person/
week)
1 
Concentration
2 
(mg/g) of 
Intake of 
EPA+DHA 
(mg/person/d)  EPA DHA 
Milk products 
Whole milk  337  0.106  0.141  11.9 
Semi-skimmed milk  877  0.045  0.060  13.2 
Skimmed milk  215  0.008  0.011  0.57 
Cream 12  1.064  1.406  4.27 
Other milk  42  0.080  0.105  1.12 
Cottage cheese  9  0.104  0.137  0.31 
Other cheese  98  0.745  0.984  24.2 
Butter 22  2.181  2.882  16.0 
Total milk products: 71.5 
Meat 
Beef and veal  249  0.24  0.053  10.4 
Sheep meat
  51 0.82  0.97  13.0 Nutrients 2009, 1                              
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Table 4. Cont. 
Pork 63  0.13  0.167  2.67 
Bacon and ham  105  0.072  0.093  2.47 
Poultry 374  0.60  0.80  74.8 
Sausages
3  68 0.012  0.015  0.26 
Other products
3  216 0.036  0.006  1.70 
Total meat products: 105.4 
Eggs  194 0.06  1.90  54.3 
Total intake: 231 
 
This shows that enrichment of animal-derived foods has the potential to provide a daily intake of 
EPA+DHA of about 230 mg/person/day with poultry meat providing the largest potential intake   
(74 mg). The contribution of poultry meat is a result of it being consumed in large quantities and its 
amenability to enrichment. Other useful contributions could be provided by eggs and full fat cheese 
although the contributions from liquid milk and other meats are likely to be very modest based on 
current food consumption data.  
 
3.3 Enrichment of Poultry Meat 
 
The concentrations of EPA and DHA in poultry meat can in theory be relatively easily increased by 
including fish oil in the diet of the birds. This can result in nutritionally meaningful increased intakes 
of these fatty acids by people who consume the meat. This topic has been reviewed recently [43]. One 
thing this review identified was the lack of data relating to the relative ability to enrich the meat of 
modern genotypes of broiler chickens and turkeys. Subsequently a study on this was done to determine 
the relative increases in the EPA and DHA in edible tissues to increased concentrations of fish oil in 
the diet [44]. Some key findings for skinless white chicken meat are shown in Table 5.  
 
Table 5. Effect of fish oil in the diet and breed of broiler chicken on the mean EPA and 
DHA concentration (mg/100g meat) in white chicken meat (from [44]). 
 Control
1  Lofish Hifish  P 
Fatty acid  Ross
2  Cobb Ross Cobb  Ross Cobb  Breed  Diet 
EPA 7.5  6.9  17.4  20.0  27.2  30.8  NS <0.001 
DHA 39.6  38.6  54.9  64.3  118  126  NS  <0.001 
1 Diets contained fish oil at Contol 0, Lofish 20 and Hifish 40 g/kg diet.  
2 Breed of birds used, Ross 308 and Cobb 500 
 
Overall, the results showed that, in modern broiler genotypes, there was no significant difference in 
the efficiency with which EPA and DHA were incorporated into edible tissue. There was also little 
evidence to suggest that there is any inherent difference between broilers and turkeys in their ability to 
incorporate EPA and DHA into their edible tissues, except perhaps for EPA in white meat. As shown Nutrients 2009, 1                              
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in Table 5, the diets containing 40 g fish oil per kg gave rise to white chicken meat containing about 
140 to 160 mg EPA+DHA per 100 g which has the potential to make a real contribution to dietary 
EPA+DHA intake. 
There are some potential drawbacks to enriching poultry meat with EPA and DHA since the meat 
will potentially have reduced oxidative stability and organoleptic qualities. Current work in this 
laboratory indicates that such problems can be minimised by use of additional vitamin E in the diet 
(~200 mg/kg) of the bird although for commercial application this will need to be coupled with 
appropriate meat processing, packaging and storage strategies. 
 
4. Conclusions 
 
Foods derived from animals are an important source of nutrients in the diet. However, certain 
aspects of some of these foods, SFA in particular, have led to concerns about the contribution of these 
foods to increased risk of CVD and other conditions. The fatty acid composition of various animal 
derived foods is not constant and can, in many cases, be enhanced by animal nutrition. The future role 
of animal nutrition in creating foods closer to the optimum composition for long term human health 
will be increasingly important. However, certain animal derived foods contain compounds which 
actively promote long term health and research is urgently required to fully characterise these effects 
and to determine how the levels in natural foods may be enhanced.  
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